EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mural Oncology's Enterprise Value is $-136.21 Mil.
Mural Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-162.29 Mil. Therefore, Mural Oncology's EV-to-FCF for today is 0.84.
The historical rank and industry rank for Mural Oncology's EV-to-FCF or its related term are showing as below:
MURA'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.16
Current: 0.84
During the past 3 years, the highest EV-to-FCF of Mural Oncology was 1.16. The lowest was 0.00. And the median was 0.00.
MURA's EV-to-FCF is ranked better than 66.58% of 395
companies
in the Biotechnology industry
Industry Median: 8.23
vs MURA: 0.84
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Mural Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mural Oncology's EV-to-FCF
For the Biotechnology subindustry, Mural Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mural Oncology's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mural Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Mural Oncology's EV-to-FCF falls into.
Mural Oncology's current Enterprise Value is $-136.21 Mil.
Mural Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-162.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mural Oncology (NAS:MURA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mural Oncology's PE Ratio for today is calculated as:
Mural Oncology's share price for today is $3.25.
Mural Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.340.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mural Oncology EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Mural Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MURA has been successfully added to your 